EP1326880A1 - Procede pour la modification selective de peptides et de proteines - Google Patents

Procede pour la modification selective de peptides et de proteines

Info

Publication number
EP1326880A1
EP1326880A1 EP01982347A EP01982347A EP1326880A1 EP 1326880 A1 EP1326880 A1 EP 1326880A1 EP 01982347 A EP01982347 A EP 01982347A EP 01982347 A EP01982347 A EP 01982347A EP 1326880 A1 EP1326880 A1 EP 1326880A1
Authority
EP
European Patent Office
Prior art keywords
proteins
peptides
ala
peptidases
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01982347A
Other languages
German (de)
English (en)
Inventor
Frank Bordusa
Hans-Dieter Jakubke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Original Assignee
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Roche Diagnostics GmbH filed Critical F Hoffmann La Roche AG
Publication of EP1326880A1 publication Critical patent/EP1326880A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)

Definitions

  • the invention relates to a method for the region-specific modification of peptides and proteins with probes and reporter molecules using biocatalysts.
  • N-terminal ⁇ -amino groups are preferred targets for selective modifications
  • the ⁇ -amino groups ubiquitously in lysine residues occurring in proteins and peptides do not allow targeted introduction of marker and reporter groups, but also other derivatizations, e.g. Pegylation, at the N-terminus.
  • Chemical acylation reactions are carried out with anhydrides or primarily with active esters, e.g. ⁇ / -Hydroxysuccinimidest- or 4-nitrophenyl esters carried out, with which other side chain functions of proteinogenic amino acid residues can also react and thus rule out a selective / ⁇ - modification.
  • the object of the invention is the regiospecific biocatalytic modification of peptides and proteins at the N-terminus while excluding side reactions as completely as possible.
  • a peptidase being the biocatalyst is used in conjunction with a non-amino acid or non-peptide-like substrate mimetic.
  • substrate mimetic was coined by Bordusa et al., Angew. Chem. 109 (1997), 2583-2585 and Bordusa et al., Angewandte Chemie International Edition in English, 36 (1997), 2473-2475.
  • Leaving group is known to the person skilled in the art and is explained by F. Bordusa, Braz. J. Med. Biol. Res. (See above) (in particular in FIG. 1).
  • the N-terminal biocatalytic modification of a peptide or protein takes place contrary to the prevailing opinion of the professional world with peptidases, the non-amino acid-like or non-peptide-like grouping to be introduced in the form of an ester derivative carrying a leaving group which carries the native specificity of the one used by targeted manipulation Turns off enzyme, thereby enabling the catalysis of an irreversible ⁇ ⁇ acylation.
  • the theoretical basis, the proposed reaction mechanism and the preparation of substrate mimetics for various proteases and peptidases is described in the review article by F. Bordusa, Brazilian Journal of Medical and Biological Research 33 (2000), 469-485.
  • the results according to the invention are very surprising.
  • a marker or reporter group all possible marker or Reporter groups are used, for example aminobenzyl, phlorethyl, biotinyl groups.
  • marker groups can be used which are required for the diagnostic use of the peptides or proteins, such as haptens (biotin, digoxin, digoxigenin, digitoxin etc.) or labels (dyes, radioactively labeled compounds, fluorescent groups, electrochemiluminescent labels (Elecsys), luminophores , Etc.).
  • Substances that change or improve the properties of proteins, such as solubility, etc. can also be selected as the marker or reporter group.
  • substances such as polyethylene glycol (PEG) and derivatives thereof can be used to optimize the properties of proteins or peptides, such as erythropoietin, insulin, monoclonal antibodies or other therapeutically active proteins and peptides. Examples of such therapeutic proteins and peptides and substances for optimizing the therapeutic effectiveness are known to the person skilled in the art.
  • Organic-chemical ester derivatives whose acyl residues correspond to the marker or reporter groups to be introduced and whose leaving groups carry specificity determinants of selected serine or cvstein peptidases are preferably used as reagents for the biocatalytic ⁇ T acylations according to the invention.
  • the terms leaving group and specificity determinants are known to the person skilled in the art (see, for example, F. Bordusa, Braz. J. Med. Biol. Res. (See above)).
  • the leaving group of a substrate mimetic binds in place of the specificity-mediating amino acid side chain of the normal substrate (Thormann et al., Biochemistry 38 (1999), 6056-6062).
  • ⁇ T-selective modifications of peptides and proteins are preferably achieved by using a carboxylic acid derivative whose carboxyl function which reacts is present as an ester with a specificity determinant in the leaving group which corresponds to the peptidase used, and a peptide or protein to be labeled in which the Reacting ⁇ -amino function is unblocked, in the presence of the corresponding peptidase, in solution at room temperature, or also in the frozen state or at low temperatures.
  • Suitable peptidases are trypsin, chymotrypsin, V8 protease, glu-specific endopeptidase from Bacillus licheniformis, subtilisin, mutants of these enzymes such as, for example, the trypsin mutant trypsin D189K + K60E (preparation see Example 9) or enzymes with similar specificity determinants.
  • the non-compliant term peptidase was used instead of proteases.
  • modified peptides and proteins can be separated and purified using conventional methods in protein chemistry.
  • Example 1 V8 protease-catalyzed N-terminal introduction of 2-aminobenzoic acid into peptides
  • 2-aminobenzoic acid carboxymethylthioester hereinafter referred to as 2-ABz-SCm
  • 2-ABz-SCm 2-aminobenzoic acid carboxymethylthioester
  • 2-ABz-SCm and amino component were used in a ratio of 2: 1 in a concentration of 4 mM and 2 mM, respectively.
  • An aqueous buffer system with a small proportion of organic solvent was used as the solvent.
  • the reaction was started by adding the enzyme and, after virtually complete conversion of 2-ABz-SCm, ended by inactivating the enzyme.
  • the analysis and quantification of the reaction was carried out using chromatographic methods.
  • the enzyme catalysis led to a 99% conversion of Leu-Ala-Leu-Ala-Ser-Ala-Ser-Ala-Phe-Gly into the corresponding N-terminal 2-ABz-modified analogues.
  • the identity of the synthesis product was checked by the usual methods of organic chemistry.
  • the carboxy component used was phloretyl-carboxymethylthioester, hereinafter referred to as phloretyl-SCm
  • the amino component was the decapeptide Leu-Ala-Leu-Ala-Lys-Ala-Asp-Ala-Phe-Gly.
  • Phloretyl-SCm and amino component were used in a ratio of 2: 1 in a concentration of 4 mM and 2 mM, respectively.
  • An aqueous buffer system with a small proportion of organic solvent was used as the solvent.
  • the reaction was started by adding the enzyme and, after virtually complete conversion of phloretyl-SCm, ended by inactivating the enzyme.
  • 2-aminobenzoic acid, 4-guanidinophenyl ester was designated as the carboxy component, hereinafter referred to as 2-ABz-OGp, and the oligopeptide Arg-Ile-Val-Asp-Ala-Val-Ile-Glu-Gln-Val-Lys as the amino component -Ala-Ala- Gly-Ala-Tyr used.
  • 2-ABz-OGp and amino component were used in a ratio of 2: 1 in a concentration of 4 mM and 2 mM, respectively.
  • An aqueous buffer system with a small proportion of organic solvent was used as the solvent.
  • the reaction was started by adding the enzyme and, after virtually complete conversion of 2-ABz-OGp, ended by inactivating the enzyme.
  • the analysis and quantification of the reaction was carried out using chromatographic methods.
  • the enzyme catalysis led to a 98.8% conversion of Arg-Ile-Val-Asp-Ala-Val-Ile-Glu-Gln-Val-Lys-Ala-Ala-Gly-Ala-Tyr into the corresponding N-terminal 2 -ABz-modified analogues.
  • the identity of the synthesis product was checked by the usual methods of organic chemistry.
  • the reaction neither led to a modification of trifunctional side chains, nor to a detectable proteolytic cleavage.
  • the carboxy component was phloretyl-4-guanidinophenyl ester, hereinafter referred to as phloretyl-OGp
  • the amino component was the oligopeptide Arg-Ile-Val-Asp-Ala-Val-Ile-Glu-Gln-Val-Lys-Ala-Ala - Gly-Ala-Tyr used.
  • Phloretyl-OGp and amino component were used in a ratio of 2: 1 in a concentration of 4 mM and 2 mM, respectively.
  • An aqueous buffer system with a small proportion of was used as the solvent organic solvent.
  • the reaction was started by adding the enzyme and, after virtually complete conversion of phloretyl-OGp, ended by inactivating the enzyme.
  • the analysis and quantification of the reaction was carried out using chromatographic methods. Enzyme catalysis led to a 99.3% conversion of Leu-Ala-Leu-Ala-Lys-Ala-Asp-Ala-Phe-Gly into the corresponding N-terminal phloretyl-modified analogues.
  • the identity of the synthesis product was checked by the usual methods of organic chemistry. The reaction neither led to a modification of trifunctional side chains, nor to a detectable proteolytic cleavage.
  • 2-aminobenzoic acid-4-guanidinophenyl ester hereinafter referred to as 2-ABz-OGp
  • 2-ABz-OGp 2-aminobenzoic acid-4-guanidinophenyl ester
  • 2-ABz-OGp 2-aminobenzoic acid-4-guanidinophenyl ester
  • 2-ABz-OGp and amino component were used in a ratio of 2: 1 in a concentration of 4 mM and 2 mM, respectively.
  • An aqueous buffer system with a small proportion of organic solvent was used as the solvent. The reaction was started by adding the enzyme and, after virtually complete conversion of 2-ABz-OGp, ended by inactivating the enzyme.
  • the analysis and quantification of the reaction was carried out using chromatographic methods.
  • the enzyme catalysis led to a 94.4% conversion of Leu-Ala-Leu-Ala-Ser-Ala-Ser-Ala-Phe-Gly into the corresponding N-terminal 2-ABz-modified analogues.
  • the identity of the synthesis product was checked by the usual methods of organic chemistry.
  • the carboxy component was phloretyl-4-guanidinophenyl ester, hereinafter referred to as phloretyl-OGp
  • the amino component was the decapeptide Leu-Ala-Leu-Ala-Ser-Ala-Ser-Ala-Phe-Gly used.
  • Phloretyl-OGp and amino component were used in a ratio of 2: 1 in a concentration of 4 mM and 2 mM, respectively.
  • An aqueous buffer system with a small proportion of organic solvent was used as the solvent.
  • the reaction was started by adding the enzyme and, after virtually complete conversion of phloretyl-OGp, ended by inactivating the enzyme.
  • the carboxyl component was BiotinyI-4-guanidinophenyl ester, hereinafter referred to as Biotinyl-OGp, and the protein E. coli Parvulin 10 was used as the amino component.
  • Biotinyl-OGp and parvulin were used in a ratio of 1: 4 in a concentration of 2mM and 8mM, respectively.
  • An aqueous buffer system with a small proportion of an organic solvent was used as the solvent.
  • 0.1 M HEPES N 2 - [2-hydroxyethyl] piperazine-N '- [2-ethanesulfonic acid
  • buffer pH 8.0 0.1 M NaCl, 0.01 M CaCl 2 and 8% (v / v) DMF (dimethylformamide) used.
  • the reaction was started by adding the enzyme trypsin D189K + K60E (trypsin mutant in which the amino acid D at position 189 has been replaced by K or K at position 60 by E; preparation see Example 9) and ended after a reaction time of 2 hours.
  • the enzyme was used in a concentration of 6.5 x 10 "6 M.
  • the analysis and quantification of the reaction was carried out by MALDI-MS spectroscopy (FIG. 1).
  • the enzyme catalysis led to a conversion of E. coli parvulin 10 into the N- terminally biotinylated biotinyl (E. coli parvulin 10).
  • E. coli parvulin 10 The primary sequence of E. coli parvulin 10 is known and corresponds to the following amino acid sequence.
  • AKTAAALHIL VKEEKLALDL LEQIKNGADF GKLAKKHSIC PSGKRGGDLG EFRQGQMVPA FDKVVFSCPV LEPTGPLHTQ FGYHIIKVLY RN
  • the protein RNase T1 was used as the carboxyl component biotinyl-OGp and as the amino component.
  • a variant with an additional Arg (R) -Gly (G) residue at the N-terminus of the protein was used for the biotinylation of RNase T1.
  • RNase T1 variant RG-RNase T1
  • G-RNase T1 and the wild type RNase T1 were also obtained. This mixture was used without separation of the individual variants for the enzyme-catalyzed biotinylation.
  • Biotinyl-OGp and RNase T1 mixture were used in a ratio of 1: 4 in a concentration of 2 mM and 8 mM, respectively.
  • An aqueous buffer system as described in Example 7 was used as the solvent.
  • the reaction was started by adding the enzyme trypsin D189K + K60E (6.5 x 10 "6 M). The reaction time was 2 hours.
  • the analysis and quantification of the reaction were carried out by chromatographic methods.
  • the electropherogram of the capillary electrophoresis carried out is shown in FIG It can be clearly seen that the RG-RNase T1 was converted almost quantitatively into the Biotinyl-RG-RNase T1.
  • the E. coli Vector pST was used to carry out the site-directed mutagenesis. This contains part of the Bluescript vector and the gene for anionic rat trypsin, which is fused to an ⁇ -factor leader and an ADH / GAPDH promoter. Protein expression was carried out using the pYT plasmid, a pBS24 derivative which carries selection markers for uracil- and leucine-deficient medium.
  • Both the pST and pYT plasmids have an ampicillin resistance gene.
  • the maps of both vectors, i.e. the plasmids pST (5.4 kb) and pYT (14 kb), with the corresponding interfaces, are shown in FIG. 3.
  • the site-directed mutagenesis was carried out using the Quik change ® kit (STRATAGENE) in the E. coli plasmid pST.
  • the method used is similar to a PCR, with two plasmid strands of the pST vector of PFU polymerase being replicated starting from two synthetic oligonucleotide primers which contain the desired mutation. Wild-type pST served as a template for generating single mutations. These single mutants were the starting point for the construction of the double mutant.
  • the PCR product obtained was transformed into ultra-competent E. coli XL II blue cells (STRATAGENE). The subsequent selection was carried out on nutrient agar plates (LB-amp) containing ampicillin. The picked colonies were transferred to a liquid medium containing ampicillin (LB-amp) and, after culturing for one day, the plasmid was isolated using the SNAP kit (INVITROGENE). The isolated DNA was checked by electrophoresis with a 1% agarose gel. By sequencing the complete gene it was possible to ensure that only the desired mutations were contained.
  • the yeast cell strain used is called Saccharomyces cerevisiae DLM 101 ⁇ [Mat a, leu 2-3, -112 to 2, 3-11, -15 can 1, ura 3 ⁇ , pep4 ⁇ , [cir °], DM 23].
  • the EZ yeast transformation kit (ZYMO-RESEARCH) was used to produce competent yeast cells and transform the pYT plasmids. The selection was made on uracil-deficient SC plates by incubation at 30 ° C. for 3 to 4 days. Single colonies were further vaccinated on leucine-deficient SC plates and also incubated for 3 to 4 days at 30 ° C, which increased the number of copies of the plasmid in the cells.
  • the cells were first separated by centrifugation for 20 min at 4000 rpm and the supernatant adjusted to pH 4.0 was centrifuged again at 12,000 rpm.
  • the practically particle-free trypsinogen-containing supernatant was applied to a Toyopearl 650 M (SUPELCO) cation exchange column equilibrated with 2 mM sodium acetate / 100 mM acetic acid (pH 4.5). Elution was carried out using a linear pH gradient starting from 2 mM sodium acetate / 100 mM acetic acid (pH 4.5) to 200 mM Tris / HCl (pH 8.0).
  • the trypsinogen-containing fractions could be determined and summarized by SDS-polyacrylamide gel electrophoresis using a 15% polyacrylamide gel.
  • the volume of the protein solutions was reduced to about 10 to 15 ml using Centriprep concentrators (AMICON).
  • the activation of the trypsinogen variant to the corresponding trypsin D189K + K60E was carried out using highly purified enterokinase (BIOZYME) at pH 6.5 and was monitored by SDS gel electrophoresis.
  • BIOZYME highly purified enterokinase
  • the activated enzyme was purified using a Biocad Sprint Perfusion Chromatography System (PERSEPTIVE BIOSYSTEMS).
  • the protein samples were separated on a POR ⁇ S 20 HQ - anion exchange column (4 x 100 mm, PERSEPTIVE BIOSYSTEMS) equilibrated with 5% bis- / tris-propane pH 6.0 and subsequent gradient elution up to 95% 3M NaCI solution.
  • the fractions containing trypsin were checked for purity using an SDS gel and pooled. Finally, dialysis was carried out against 1 mM HCI at 4 ° C and concentration of the samples with Centriprep concentrators to 2 to 4 ml.
  • the final yields were about 2 to 5 mg protein per liter of culture medium.
  • the protein concentration of the preparations was determined using the Bradford method on a spectrophotometer at a wavelength of 595 nm.
  • the calibration curve was recorded using a series of bovine trypsin dilutions between 50 ⁇ m / ml and 1 mg / ml.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé pour la modification spécifique à une région de peptides et de protéines à l'aide de sondes et de molécules rapporteuses en utilisant des peptidases en liaison avec un analogue de substrat qui n'est pas de type amino-acide ou peptide.
EP01982347A 2000-09-27 2001-09-25 Procede pour la modification selective de peptides et de proteines Withdrawn EP1326880A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10047857A DE10047857B4 (de) 2000-09-27 2000-09-27 Verfahren zur selektiven biokatalytischen Modifizierung von Peptiden und Proteinen
DE10047857 2000-09-27
PCT/EP2001/011035 WO2002026772A1 (fr) 2000-09-27 2001-09-25 Procede pour la modification selective de peptides et de proteines

Publications (1)

Publication Number Publication Date
EP1326880A1 true EP1326880A1 (fr) 2003-07-16

Family

ID=7657835

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01982347A Withdrawn EP1326880A1 (fr) 2000-09-27 2001-09-25 Procede pour la modification selective de peptides et de proteines

Country Status (7)

Country Link
US (1) US20040077037A1 (fr)
EP (1) EP1326880A1 (fr)
JP (1) JP2004509973A (fr)
AU (1) AU2002213954A1 (fr)
CA (1) CA2421676A1 (fr)
DE (1) DE10047857B4 (fr)
WO (1) WO2002026772A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
CA2414076A1 (fr) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Molecules a plate-forme polyvalentes comprenant un poly(ethylene oxyde) de poids moleculaire eleve
DE10240098B4 (de) * 2002-08-30 2006-04-06 Roche Diagnostics Gmbh Verfahren zur Synthese und selektiven biokatalytischen Modifizierung von Peptiden, Peptidmimetika und Proteinen
US20110045530A1 (en) * 2008-02-13 2011-02-24 Peter Jan Leonard Mario Quaedflieg Enzymatic conjugation of bioactive moieties
WO2013192430A2 (fr) * 2012-06-20 2013-12-27 The Regents Of The University Of California Catalyseur biomimétique dynamique de type synzyme, catalyse, et systèmes catalytiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD295165A5 (de) * 1990-06-13 1991-10-24 ���������`��������`����@����k�� Verfahren zur herstellung von peptiden
DK67691D0 (da) * 1991-03-01 1991-04-15 Carlbiotech Ltd As Enzymatisk fremgangsmaade til c-terminal modificering af peptider og mellemprodukter til brug ved fremgangsmaaden
US5985627A (en) * 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
DE19834308C2 (de) * 1998-07-30 2002-11-07 Univ Leipzig Verfahren zur Herstellung von Säureamiden

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0226772A1 *

Also Published As

Publication number Publication date
DE10047857A1 (de) 2002-04-18
AU2002213954A1 (en) 2002-04-08
WO2002026772A1 (fr) 2002-04-04
CA2421676A1 (fr) 2002-04-04
US20040077037A1 (en) 2004-04-22
JP2004509973A (ja) 2004-04-02
DE10047857B4 (de) 2004-11-18

Similar Documents

Publication Publication Date Title
Beauvais et al. Dipeptidyl-peptidase IV secreted by Aspergillus fumigatus, a fungus pathogenic to humans
CA2074943C (fr) Procede pour le clivage enzymatique des proteines recombinantes a l'aide de proteases iga
US5512459A (en) Enzymatic method for modification or recombinant polypeptides
DE60208343T2 (de) FUSIONSPROTEINE aus hirudin und proinsulin oder insulin
US5270176A (en) Method for the selective cleavage of fusion proteins with lysostaphin
AU666274B2 (en) Process for producing hydrophobic polypeptides, proteins or peptides
JPH06315384A (ja) セリンプロテアーゼインヒビターの産生のための遺伝子組み換え法と、同じ目的に有用なｄｎａ塩基配列
JP2787585B2 (ja) ヒトｅｇｆの製造法
EP0329693A1 (fr) Inhibiteurs de la trypsine secretrice pancreatique humaine produits par des methodes d'adn recombinant et procede de production de ces inhibiteurs
WO2002026772A1 (fr) Procede pour la modification selective de peptides et de proteines
JPS62278986A (ja) ハイブリツドポリペプチド
JPH04258296A (ja) プレプロインスリンのインスリンへの酵素的変換方法
AU618035B2 (en) A method for the selective cleavage of fusion proteins
US8530217B2 (en) Processing of peptides and proteins
EP1326995B1 (fr) Procede de synthese de peptides, peptides mimetiques et proteines
EP1169461B1 (fr) Utilisation de procarboxypeptidase B pancréatique pour la production d'insuline
RU2120475C1 (ru) Способ получения представляющего интерес полипептида, гибридная днк (варианты), слитый белок (варианты)
AU650150B2 (en) Novel endopeptidase
Yuuki et al. Purification and some properties of two enzymes from a β-glucanase hyperproducing strain, Bacillus subtilis HL-25
JPH0648988B2 (ja) トロンビン阻害物質の製造法
Kim et al. Secretory expression of active clostripain in Escherichia coli
DE60120456T2 (de) Neue lösliche endoproteasen für die in vitro prozessierung von rekombinanten proteinen
KR20040079889A (ko) 콜리신 프로모터를 이용한 단백질 분해효소의 대량 생산을위한 재조합 단백질의 발현시스템.
JPS61181396A (ja) 精製蛋白質の製造法
DE4325746A1 (de) Verfahren zur Herstellung von Peptiden und Verwendung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030428

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: F.HOFFMANN-LA ROCHE AG

Owner name: ROCHE DIAGNOSTICS GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060322